Editas Medicine (EDIT) Profit After Tax (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Profit After Tax of -$25.1 million for Q3 2025, up 59.58% year-over-year from -$15.7 million in Q3 2024, and up 52.82% quarter-over-quarter from -$53.2 million in Q2 2025.
Editas Medicine (EDIT) Profit After Tax (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Profit After Tax for 11 consecutive years, with -$25.1 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Profit After Tax rose 59.58% year-over-year to -$25.1 million; the TTM figure through Sep 2025 stood at -$199.8 million (up 5.1% YoY), while the FY2024 annual figure was -$237.1 million, down 54.74% from the prior year.
- Profit After Tax advanced to -$25.1 million in Q3 2025 per EDIT's latest filing, from -$53.2 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$18.9 million in Q4 2023 and bottomed at -$76.1 million in Q1 2025.
- Historically, Profit After Tax has averaged -$50.4 million across 5 years, with a median of -$53.2 million in 2025.
- Annual changes were most pronounced in 2021 — Profit After Tax sank 599.83% — and 2023, when it jumped 68.93%.
- Editas Medicine's Profit After Tax stood at -$41.4 million in 2021, then plunged by 46.58% to -$60.7 million in 2022, then surged by 68.93% to -$18.9 million in 2023, then tumbled by 140.52% to -$45.4 million in 2024, then surged by 44.67% to -$25.1 million in 2025.
- Business Quant data shows EDIT's Profit After Tax at -$25.1 million in Q3 2025, -$53.2 million in Q2 2025, and -$76.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -25.12 Mn |
| Jun 30, 2025 | -53.24 Mn |
| Mar 31, 2025 | -76.09 Mn |
| Dec 31, 2024 | -45.40 Mn |
| Sep 30, 2024 | -62.14 Mn |
| Jun 30, 2024 | -67.61 Mn |
| Mar 31, 2024 | -61.95 Mn |
| Dec 31, 2023 | -18.87 Mn |
| Sep 30, 2023 | -45.02 Mn |
| Jun 30, 2023 | -40.29 Mn |
| Mar 31, 2023 | -49.04 Mn |
| Dec 31, 2022 | -60.74 Mn |
| Sep 30, 2022 | -55.73 Mn |
| Jun 30, 2022 | -53.45 Mn |
| Mar 31, 2022 | -50.52 Mn |
| Dec 31, 2021 | -41.44 Mn |
| Sep 30, 2021 | -39.08 Mn |
| Jun 30, 2021 | -55.26 Mn |
| Mar 31, 2021 | -56.73 Mn |
| Dec 31, 2020 | -62.50 Mn |